Key Findings from ASH 2025 in AML: Canadian Experts Weigh In

Key Findings from ASH 2025 in AML: Canadian Experts Weigh In

Key Findings from ASH 2025 in AML: Canadian Experts Weigh In
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Objectives

Learning Objectives

  1. Summarize the most impactful AML data presented at ASH 2025, including updates in frontline and relapsed/refractory settings.
  2. Discuss the most significant abstracts presented at the 2025 ASH in AML.
  3. Interpret new clinical trial results in AML through a Canadian clinical practice lens.
Icon Chair Speaker

Moderators

Dr. Michelle Geddes

Icon Chair Speaker

Speakers

Dr. Brian Leber

Studies / Trials Discussed

Abstract 42
Outcomes of Patients with Relapsed/Refractory FLT3mut+ Acute Myeloid Leukemia Who Resumed Gilteritinib Therapy After HSCT: Post Hoc Analysis from the ADMIRAL and COMMODORE Trials

Abstract 654
Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed (ND) FLT3mut+ acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy (chemo): Interim results from the phase 1/2 VICEROY study

Abstract 39
The outcomes of patients who are relapsed or refractory to menin inhibitors is poor with a limited overall survival

Abstract 345
FLT3-ITD NGS-MRD refines risk stratification in NPM1 and FLT3 co-mutated AML beyond NPM1 PCR-MRD: Analysis of the UK NCRI AML17 and AML19 trials”

This program has been made possible through unrestricted support from Astellas.

Studies/trials discussed:

Abstract 42 Outcomes of Patients with Relapsed/Refractory FLT3mut+ Acute Myeloid Leukemia Who Resumed Gilteritinib Therapy After HSCT: Post Hoc Analysis from the ADMIRAL and COMMODORE Trials Abstract 654 Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed (ND) FLT3mut+ acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy (chemo): Interim results from the phase 1/2 VICEROY study Abstract 39 The outcomes of patients who are relapsed or refractory to menin inhibitors is poor with a limited overall survival Abstract 345 FLT3-ITD NGS-MRD refines risk stratification in NPM1 and FLT3 co-mutated AML beyond NPM1 PCR-MRD: Analysis of the UK NCRI AML17 and AML19 trials”
Tagged